Effect of the Drug Decoglitz on Rats with Tumor Sarcoma 45 and its Action on NA Synthesis
Purpose of work. Assessment of the antitumor activity of the new drug Decoglitz in animals with the tumor strain Sarcoma 45 in comparison with the drug dekocin, from which it was obtained, as well as with 5-fluorouracil and etoposide, and the identification of their effect on the synthesis of nucleic acids (NA). Materials and methods. The study was carried out on 48 outbred rats with a C-45 transplantable tumor, which were injected 10 times on the 4th day after tumor transplantation. The results were evaluated according to standard criteria: tumor growth inhibition (TPI), body weight and spleen of animals. Differences at p<0.05 were considered reliable. Alkylating effect of drugs on DNA and RNA synthesis was studied using a spectrophotometric method on Sarcoma 180 tumor cells. Internucleosomal DNA degradation of sarcoma 180 cells after drug exposure was studied using the method of Samusenko A.V.Results. The antitumor activity of the drug Decoglitz on the tumor strain Sarcoma 45 in the early period was high - about 98/96% with a remission rate of 80%. Its effect was 28-24% higher than that of decocin, with a decrease in the level of side effects. 5-fluorouracil and etoposide caused an effect of 76-78%, however, with the death of animals, more in the case of 5-fluorouracil. This effect is confirmed by the more intense effect of Decoglitz on the synthesis of NA, which is 8-15% more than that of decocin, 10-40% more than that of etoposide taken as a control, and 37-55% more than at the glycyrrhizin acid (GA). Conclusion. The study of the new drug Decoglitz on animals with a tumor of Sarcoma 45 revealed its higher activity (by 20-27%) in comparison with the original Dekocin, 5-fluorouracil and etoposide with a lower level of side effects. Apparently, the great ability to suppress the synthesis of nucleic acids (NK) and to carry out internucleosomal degradation and fragmentation of tumor DNA by the new drug Dekogliz explains its antitumor efficacy, which is greater than that of Dekocin (K-18) in experiments on tumors.